Our mission is to detect cancer early, when it can be cured.
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to screen for many of the deadliest cancer types before symptoms appear.
Our history
Our story began in 2015, when an unexpected discovery unlocked a major breakthrough for changing lives at population scale.
The Galleri® test
Revolutionizing what’s possible in cancer screening with a first-of-its-kind, Multi-Cancer Early Detection (MCED) test.
Backed by rigorous clinical evidence
>300 scientific publications and presentations
>385K participants across unprecedented clinical program
Locations
>170,000 square feet of CAP-accredited, CLIA-certified lab facilities with sufficient capacity to support multiple years of growth.
Leadership
Our leadership team is driven by a common purpose – to advance technology that can help detect cancer early.
Join our team
2025 Best Place to Work Lists Built In & BioSpace
Our talented employee pool includes expertise from individuals with a variety of backgrounds and specialties, enriching our collective knowledge and skill-base.
2023 Change the World List, Fortune
2022 World Changing Ideas Awards, Fast Company
Breakthroughs of the Year List, 2022, The Atlantic
Intelligent Diagnostics Silver Winner, 2023, The Edison Awards
Best Inventions of 2022 List, Time Magazine
Error: Contact form not found.
Explore more
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
